Production of optically active sphingoid compound

Abstract: An industrially advantageous production method of an optically active alcohol useful for cosmetics and medical supplies or production intermediates thereof using an esterase having an ability to selectively hydrolyze an optically active sphingoid compound.

Description: BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to a method for producing an optically active sphingoid compound. Description of the Related Art Optically active sphingoid compounds having optically active erythro amino alcohol moiety have been used in cosmetics and medical supplies for treatment of hair and skin or production intermediates thereof. Conventionally, these compounds are extracted and separated mainly from epidermis tissue of animals such as cows and pigs, alternatively obtained by several synthetic steps.However, they are expensive and a stable supply thereof is difficult since the production amount is limited. Therefore, a a further provision of a convenient method for producing the said compound has been desired. EP0189878, EP 0765857 and EP 0845534 disclose the preparation of optically active compounds by means of stereoselective enzymes. However, none of these compounds are structurally related to sphingoid derivatives. SUMMARY OF THE INVENTION An object of the present invention is to provide: a method for producing an optically active erythro sphingoid ester of the formula I: wherein R 1 and R 2 may be the same or different and represent an aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, and R 3 and R 4 may be the same or different and represent an acyl group having 1 to 7 carbon atoms, which comprises: allowing a racemic mixture comprising the optically active erythro sphingoid ester of the formula I as defined above and its enantiomer to contact with an esterase having the ability to selectively hydrolyze the said enantiomer of the optically active erythro sphingoid ester of the formula I to produce an optically active erythro sphingoid alcohol compound of the formula II: wherein R 1 and R 2 have the same meaning as defined above, and R 3 and R 4 represent a hydrogen atom and an acyl group having 1 to 7 carbon atoms provided that R 3 * and R 4 * do not simultaneously represent an acyl group having 1 to 7 carbon atoms; and recovering the optically active erythro sphingoid ester of the formula I. DESCRIPTION OF THE PREFERRED EMBODIMENT Next, a description will be made to the racemic mixture comprising the optically active erythro sphingoid ester compound of the formula I as defined above and its enantiomer represented by the formula II as defined above. Examples of the aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, represented by R 1 and R 2 , for example, include: a liner or branched alkyl group having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, a liner or branched alkenyl group having 7 to 31 carbon atoms which has one or more double bonds and may be substituted by one or more hydroxyl groups, A liner or branched alkyl group having 7 to 31 carbon atoms which may be substituted by one to three hydroxyl groups, a liner or branched alkenyl group having 7 to 31 carbon atoms which has one to three double bonds and may be substituted by one to three hydroxyl groups, are preferred. Among the aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, for R 1 and R 2 , the aliphatic hydrocarbon having 7 to 26 carbon atoms which may be substituted by one or more hydroxyl groups are preferred. Specific examples of the above-described preferred alkyl or alkenyl groups include: a heptyl group, tridecyl group, tetradecyl group, pentadecenyl group, hexadecyl group, heptadecyl group, octadecyl group, nonadecyl group, eicosyl group, heneicosyl group, docosyl group, tricosyl group, tetracosyl group, pentacosyl group, hexacosyl group, heptacosyl group, octacosyl group, nonacosyl group, tracontyl group, hentriacontyl group, 1-tridecenyl group, 1-tetradecenyl group, 1-pentadecenyl group, 1-hexadecenyl group, 1-heptadecenyl group, 1-octadecenyl group, 1-nonadecenyl group, 1-eicosenyl group, 1-hydroxytetradecyl group, 1-hydroxypentadecyl group, 1-hydroxthexadecyl group, 1-hydroxtheptadecyl group, 1-hydroxyoctadecyl group, 1-hydroxynondecyl group, 1-hydroxyeicosyl group, 1-hydroxtheneicosyl group, 1-hydroxydocosyl group, 1-hydroxytricosyl group, 1-hydroxytetracosyl group, 1-hydroxypentacosyl group, 1-hydroxyhexacosyl group, 1-hydroxyheptacosyl group, 12-methyl-tridecyl group, 14-methy-1-pentadecenyl group, 14-methyl-heptadecyl group and the like. Examples of the acyl group having 1 to 7 carbon atoms for R 3 and R 4 include an alkylcarbonyl group having 2 to 7 carbon atoms. Specific examples of the acyl group include an acetyl group, propionyl group, butyryl group. An acetyl group is more preferred. Specific examples of the racemic erythro sphingoid ester include: N-heptadecanoyl-1,3-O,O-diacetyl-2-amino-4-hexadecene-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol, N-heptadecanoyl-1, 3-O,O-diacetyl-2-aminoeicosane-1, 3-diol, N-heptadecanoyl-1,3-O,O-dibutyryl-2-aminoeicosane-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-aminoheptacosane-1 ,3-diol, N-octadecanoyl-1,3-O,O-diacetyl-2-amino-15-methylhexadecane-1,3-diol, N-octadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol, N-octadecanoyl-1, 3.-O,O-dibutyryl-2-aminohexadecane-1 , 3-diol, N-octadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol, N-octadecanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol, N-octadecanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol, N-octadecanoyl-1,3-O,O-dibutyryl-2-aminoheptacosane-1,3-diol, N-2'-hydroxyoctadecanoyl-1 ,3-O,O-diacetyl-2-amino-15 methylhexadecane-1,3-diol, N-2'-hydroxyhexadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol, N-2'-hydroxyhexadecanoyl-1,3-O,O-dibutyryl-2-aminohexadecane-1,3-diol, N-2 '-hydroxyeicosanoyl-1, 3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol, N-2'-hydroxyeicosanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol, N-2'-hydroxytetracosanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol, N-2'-hydroxyhexacosanoyl-1,3-O,O-dibutyryl-2-aminoheptacosane-1,3-diol, N-docosanoyl-1,3-O,O-dibutyryl-2-amino-15-methyhexadecane-1,3-diol, N-tetracosanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol, N-hexacasanoyl-1,3-O,O-dibutyryl-2-aminohexadecane-1,3-diol, N-methyloctadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol, N-pentacosanoyl-1,3-O,O-diacetyl-2-amino-4-docosene-1,3-diol, N-pentacosanoyl-1, 3-O,O-diacetyl-2-amino-4-octadeaeme-1,3-diol, N-pentacosanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol. These sphingoid esters can be obtained, for example, by a method disclosed by T. Kolter et al. (Tetrahedron, 50, p.13425 (1994)). The esterase includes an esterase, protease and the like in addition to a narrowly-defined lipase, and may be derived from animals such as hogs, human and the like, derived from plants such as ricinus, or derived from microorganisms belonging to Aspergillus, Candida , Fusarium, Geotrichum, Mucor, Nocardia, Penicillium, Rhizopus, Saccharomyces, Acromobacter, Acinetobacter, Alcaligenes, Chromobacterium, Escherichia, Pseudomonas, Sphingomonas, Bacillus, Burkholderia, Moraxella, Lactobacillus, Staphylococcus, Serratia, Yarrowia . An esterase produced by a transformed host organism, into which an isolated gene of the esterase is introduced by using recombinant DNA technology, can be used in the present invention. As the host organism, an organism belonging to the same genus or a host organism belonging to the different genus can be used. As a more specific example of the esterase, a protein having an amino acid sequence represented by SEQUENCE ID NO: 1 or a sequence in which one or more amino acids in the amino acid sequence are added, deleted or substituted, is listed.. A microorganism ( E. coli JM 109/pAL 612 strain) producing the protein having the amino acid sequence represented by SEQUENCE ID NO: 1 has been deposited as FERM-BP5740 (accepted date: November 7, 1996) under the Budapest Treaty at the Ministry of International Trade and Industry, Agency of Industrial Science and Technology, National Institute of Biochemical and Human-Technology. The esterase may be used in the form of a microorganism containing the same or a cell culture, however, it may also be separated from the culture or tissue containing the esterase and utilized in the form of a crude enzyme, purified enzyme, if necessary. These crude enzyme, purified enzyme and the like can be prepared by a conventional method such as, for example, (1) ultrasonic treatment, (2) grinding treatment using glass beads or alumina, (3) French press treatment, (4) treatment with an enzyme such as lysozyme and the like, (5) bacteria, cell, tissue or the like is ground by Waring blender treatment and the like, (6) the resulted ground material is salted out using ammonium sulfate, (7) precipitation by an organic solvent or an organic polymer such as polyethylene glycol, (8) various chromatographies such as ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, affinity chromatography, and (9) electrophoresis and the like. The esterase may be insolubilized by a immobilization such as a carrier binding method in which the esterase is bound to a carrier by a covalent bond, ion bond, adsorption and the like, an entrapment method in which the esterase is confined in gel structure. The reaction is usually carried out from about 20°C to about 70°C, preferably from about 25°C to about 40°C. The reaction is preferably conducted in a two-layer system comprising an organic solvent which dissolves the sphingoid ester compound of the formula I as defined above and its enantiomer and a buffer solution which dissolves the above-described esterase. Examples of the organic solvent include, for example, decane. Examples of the buffer solution include a usual buffer solution having pH of 5 to 8. The reaction time can be optionally set, for example, from about 1 hour to 1 week. For recovery of the optically active erythro sphingoid ester of the formula I from the reaction solution, conventional methods such as, for example, solvent extraction, fractional distillation, column chromatography and the like may be used, and optionally, these methods may also be appropriately combined for use, if necessary. The optically active erythro sphingoid ester of the formula I as defined above can be allowed to react with either an acid or a base to effect a hydrolysis reaction by a conventional method to obtain an optically active erythro sphingoid alcohol of the formula I': wherein R 1 and R 2 are the same as defined for the formula I above. Examples of thus obtained optically active erythro sphingoid alcohols includes optically active erythro isomers of the following compounds such as: N-heptadecanoyl-2-amino-4-hexadecene-1,3-diol, N-heptadecanoyl-2-aminohexadecane-1,3-diol, N-heptadecanoyl-2-amino-4-octadecene-1, 3-diol, N-heptadecanoyl-2-aminooctadecane-1,3,4-triol, N-heptadecanoyl-2-aminoeicosane-1,3-diol, N-heptadecanoyl-2-aminoeicosane-1, 3-diol, N-heptadecanoyl-2-aminoheptacosane-1,3-diol, N-octadecanoyl-2-amino-15-methylhexadecane-1,3-diol, N-octadecanoyl-2-aminohexadecane-1,3-diol, N-octadecanoyl-2-amino-4-octadecene-1,3-diol, N-octadecanoyl-2-aminooctadecane-1,3,4-triol, N-octadecanoyl-2-aminaeicoBane-1,3-diol, N-octadecanoyl-2-aminoheptacosane-1,3-diol, N-2'-hydroxyoctadecanoyl-2-amino-15-methylhexadecane-1,3-diol, N-2'-hydroxyhexadecanoyl-2-aminohexadecane-1,3-diol, N-2'-hydroxyeicosanoyl-2-amino-4-octadecene-1,3-diol, N-2'-hydroxyeicosanoyl-2-aminooctadecane-1,3,4-triol, N-2'-hydroxytetracosanoyl-2-aminoeicosane-1,3-diol, N-2 '-hydroxyhexaconoyl-2-aminoheptacosane-1, 3-diol N-docosanoyl-2-amino-15-methyhexadecane-1,3-diol, N-tetracosanoyl-2-aminohexadecane-1,3-diol, N-hexacosanoyl-2-aminohexadecane-1,3-diol, N-methyloctadecanoyl-2-amino-4-octadecene-1,3-diol, N-pentacosanoyl-2-amino-4-docosene-1,3-diol, N-pentacosanoyl-2-amino-4-octadecene-1,3-diol, N-pentacosanoyl-2-aminoeicosane-1,3-diol. EXAMPLE The following examples further illustrate the present invention in detail, but they are not to be construed to limit the scope thereof. Example 1 To a mixed solution of 10 ml decane and 100 ml of a phosphate buffer solution were added 1.03 g of racemic erythro-3-acetoxy-2-stearoylaminohexadecyl acetate and 50 mg of an esterase prepared in Reference Example 1 below, and the resulted mixture was reacted by stirring at 30°C. The reaction was traced by TLC [silica gel, hexane : ethyl acetate (2:1), chloroform : methanol (15:1)]. The reaction was continued for 2 days, and then, the reaction solution was diluted with ethyl acetate, and then extracted with chloroform. The recovered organic solvent layer was washed with salt water, then, dried over anhydrous sodium sulfate, and the filtered solution was concentrated under reduced pressure to obtain a residue. The resulted residue was separated by silica gel column chromatography using hexane : ethyl acetate (5:1) and chloroform : methanol (30:1) as eluent. A sample of the eluted (+)- (2S , 3R) erythro-3-acetoxy-2-stearoylaminohexadecyl acetate (264.9 mg) was hydrolyzed, then converted to (4R, 5S)-erythro-2,2-dimethyl-5-stearoylamino-4-tridecyl-1,3-dioxane in the presence of p-toluenesulfonic acid, 2,2-dimethoxypropane and acetone, and the optical purity was analyzed by 1 H-NMR to find it was >95%e.e. Then, a sample of the eluted (-)-(2R,3S)-3-acetoxy 2-stearoylaminohexadecane-1-ol (481.8 mg) was hydrolyzed, and compared with angle of rotation of (-)-(2R,3S)-erythro-2-stearoylamino-113-hexadecanediol, to find a optical purity of 16%e-e. Then, a part of the eluted (-)-(2R,3s)-erythro-2-stearoylamino-1,3-hexanediol (214.8 mg) was converted to (4S,5R)-erythro-2,2-dimethyl-5-stearoylamino-4-tridecyl-1,3-dioxane according to the method as described above. The optical purity was analyzed by 1 H-NMR to find it was >95%e.e. Example 2 To a mixed solution of 10 ml decane and 100 ml of a phosphate buffer solution were added 10.2 mg of racemic erythro-3-acetoxy-2-stearoylaminohexadecyl acetate and 10.8 mg of an immobolized esterase prepared in Reference Example 2 below, and the resulted mixture reacted under stirring at 30°C. The reaction was traced by TLC [silica gel, hexane : ethyl acetate (2:1), chloroform : methanol (15:1)]. The reaction was continued for 2 days, and then, the product (+)-(2S,3R)-erythro-3-acetoxy-2-stearoylaminohexadecyl acetate was separated according to the method described in Example 1. Then a sample of the separated product was hydrolyzed, then reacted with α-methoxy-α-trifluoromethylphenyl acetate (hereinafter, referred to as MTPA), converted to a bis-MTPA ester, then, optical purity was analyzed by 1 H-NMR. (+)- (2S, 3R)-erythro-2-acetoxy-2-stearoylaminohexadecyl acetate was obtained in a yield of 50%, and the optical purity was >95%e.e. Reference Example 1 : Preparation of esterase Recombinant E. coli JM109/pAL612 strain (FREM-BP 5740) was incubated in 100 ml of a LB medium (manufactured by Difco) containing 50 mg/L of ampicillin and 1 mM of isopropyl thio-β-D-galactoside, at 37°C for 16 hours, then the culture was subjected to centrifuged (6000 rpm, 10 minutes) to recover microorganism. The recovered microorganism was suspended in a 10 ml of 100 mM phosphate buffer solution (pH 7.0), then was broken by ultrasonic wave, and the broken material was centrifuged to obtain a crude enzyme extract solution. Then, the resulted crude enzyme extract solution was freeze-dried to obtain a crude enzyme powder. Reference Example 2: Immobilization of esterase To a 10 ml of 0.1 M phosphate buffer solution (pH 7.0) into which Triton X-100 (TRM of Union Carbide Chemicals and Plastics) (300 mg) was dissolved was added 1 g of the enzyme powder obtained in Reference Example 1, then, Florysil (TRM of U.S. Silica Company, purchased from Aldrich Japan) (8.7 mg) was added in ice water. The resulted mixture was frozen at -78°C, then freeze-dried to obtain 1.4 g of an immobilized powdery enzyme.

Claims: A method for producing an optically- active erythro sphingoid ester of the formula I: wherein R 1 and R 2 , are the same or different, represent an aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups, and R 3 and R 4 , may be the same or different and represent an acyl group having 1 to 7 carbon atoms, which comprises: allowing a racemic mixture comprising the optically active sphingoid ester of the formula I as defined above and its enantiomer to contact with an esterase having an ability to selectively hydrolyze said enantiomer of the optically active sphingoid ester of the formula I to produce an optically active sphingoid alcohol compound of the formula II: wherein R 1 and R 2 have the same meaning as defined above, and R 3 * and R 4 * . represent a hydrogen atom or an acyl group having 1 to 7 carbon atoms provided that R 3 * and R 4 * , do not simultaneously represent an acyl group having 1 to 7 carbon atoms; and recovering the optically active erythro sphingoid ester of the formula I, wherein said enzyme is an enzyme (a) comprising an amino acid sequence of SEQUENCE ID NO: 1: or (b) comprising an amino acid sequence of SEQUENCE ID NO: 1 with addition, deletion or substitution of one or more amino acids: or (c) obtainable from: 1) an animal, 2) plant, or 3) a microorganism belonging to Aspergillus, Candida, Fusarium, Geotrichum, Mucor, Nocardia, Penicillium, Rhizopus, Saccharomyces, Acromobacter, Acinetobacter, Alcaligenes, Chromobacterium, Escherichia, Pseudomonas, Sphingomonas, Bacillus, Burkholderia, Moraxella, Lactobacillus, Staphylococcus, Serratia, or Yarrowia, or (d) obtainable from FERM-BP 5740. A method for producing an optically active erythro sphingoid alcohol of the formula I': wherein R 1 and R 2 are the same as defined in claim 1, which comprises: allowing the recovered optically active erythro sphingoid ester of the formula I as defined in claim 1 to a hydrolysis reaction. The method according to Claim 1, wherein the esterase is a protein having an amino acid sequence of SEQUENCE ID NO: 1, or an amino acid sequence of SEQUENCE ID NO: I with addition, deletion or substitution of an amino acid. The method according to Claim 2, wherein the esterase is a protein having an amino acid sequence of SEQUENCE ID NO: 1, or an amino acid sequence of SEQUENCE ID NO : 1 with addition, deletion or substitution of an amino acid. The method according to claim 1, which further comprises the step of reacting the recovered optically active erythro sphingoid ester of the formula I to a hydrolysis reaction to produce an optically active erythro sphingoid alcohol of the formula I': wherein R 1 and R 2 are the same or different, represent an aliphatic hydrocarbon having 7 to 31 carbon atoms which may be substituted by one or more hydroxyl groups. The method according to claim 1 or 5, wherein the racemic sphingoid ester is: N-heptadecanoyl-1,3-O,O-diacetyl-2-amino-4-hexadecene-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol, N-heptadecanoyl-1,3-O, O-diacetyl-2-aminoeicosane-1, 3-diol, N-heptadecanoyl-1,3-O,O-dibutyryl-2-aminoeicosane-1,3-diol, N-heptadecanoyl-1,3-O,O-diacetyl-2-aminoheptacosane-1.3-diol, N-octadecanoyl-1,3-O,O-diacetyl-2-amino-15-methylhexadecane-1, 3 -diol, N-octadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1,3-diol, N-octadecanoyl-1, 3-O,O-dibutyryl-2-aminohexadecane-1,3-diol. N-octadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1-3-diol, N-octadecanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1,3,4-triol, N-octadecanoyl-1, 3-O,O-diacetyl-2-aminoeicosane-1, 3-diol, N-octadecanoyl-1, 3-O,O-dibutyryl-2-aminoheptacosane-1,3-diol, N-2'-hydroxyhexadecanoyl-1,3-O,O-diacetyl-2-amino-15-methylhex adecane-1-3-diol, N-2'-hydroxyhexadecanoyl-1,3-O,O-diacetyl-2-aminohexadecane-1, 3-diol, N-2'-hydroxyhexadecanoyl-1,3-O,O-dibutyryl-2-aminohexadecane-1 ,3-diol, N-2'-hydroxyeicosanoyl-1, 3-O, O-diacetyl-2-amino-4-octadecene-1 , ,3-diol, N-2'-hydroxyeicosanoyl-1,3-O,O-diacetyl-2-aminooctadecane-1, 3, 4-triol, N-2'-hydroxytetracosanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1, 3 -diol, N-2' -hydraxyhexadecanayl-1,3-O,O-dibutyryl-2-aminoheptacosane-1, 3-diol, N-docosanoyl-1,3 -O, O-dibutyryl-2-amino-15-methyhexadecane-1,3-diol, N-tetracosanoyl-1. 3-O,O-diacetyl-2-aminohexadecane-l, 3-diol, N-hexacosanoyl-1,3-O,O-dibutyryi-2-aminohexadecane-1,3-diol, N-methyloctadecanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3 -diol, N-pentacosanoyl-1,3-O,O-diacetyl-2-amino-4-docosene-1,3-diol, N-pentacosanoyl-1,3-O,O-diacetyl-2-amino-4-octadecene-1,3-diol, or N-pentacosanoyl-1,3-O,O-diacetyl-2-aminoeicosane-1,3-diol. The method according to claim 1 or 5, wherein the acyl group represented by R3, R4, R3 * , or R4 * is an acetyl group. The method according to claim 2 or 5, wherein the optically active erythro sphingoid alcohol of the formula I' is an optically active erythro isomer of: N-heptadecanoyl-2-amino-4-hexadecene-1,3-diol, N-heptadecanoyl-2-aminohexadecane-1,3-diol, N-heptadecanoyl-2-amino-4-octadecene-1,3-diol, N-heptadecanoyl-2-aminooctadecane-1,3,4-triol, N-heptadecanoyl-2-aminoeicosane-1,3-diol, N-heptadecanoyl-2-aminoeicosane-1,3-diol, N-heptadecanoyl-2-aminoheptacosane-1,3-diol, N-octadecanoyl-2-amino-15-methylhexadecane-1,3-diol, N-octadecanoyl-2-aminohexadecane-1,3-diol, N-octadecanoyl-2-amino-4-octadecene-1,3-diol, N-octadecanoyl-2-aminooctadecane-1,3,4-triol, N-octadecanoyl-2-aminoeicosane-1,3-diol, N-octadecanoyl-2-aminoheptacosane-1,3-diol, N-2' -hydroxyoctadecanoyl-2-amino-15-methylhexadecane-1,3-diol, N-2'-hydroxyhexadecanoyl-2-aminohexadecane-1,3-diol, N-2'-hydroxyeicosanoyl-2-amino-4-octadecene-1,3-diol, N-2'-hydroxyeicosanoyl-2-aminooctadecane-1,3,4-triol, N-2'-hydroxytetracosanoyl-2-aminoeicosane-1,3-diol, N-2'-hydroxyhexaconoyl-2-aminoheptacosane-1,3-diol, N-docosanoyl - 2 - amino-15 -methyhexadecane-1, 3-diol, N-tetracosanoyl-2-aminohexadecane-1,3-diol, N-hexacosanoyl-2-aminohexadecane-1,3-diol, N-methyloctadecanoyl-2-amino-4-octadecene-1,3-diol, N-pentacosanoyl-2-amino-4-docosene-1,3-diol, N-pentacosanoyl-2-amino-4-octadecene-1,3-diol, or N-pentacosanoyl-2-aminoeicosane-1,3-diol. The method according to claim 1 or 5, wherein said enzyme is an enzyme comprising an amino acid sequence of SEQUENCE ID NO: 1. The method according to claim 1 or 5, wherein said enzyme is an enzyme comprising the amino acid sequence of SEQUENCE ID NO: 1 with addition, deletion or substitution of an amino acid. The method according to claim 1 or 5, wherein said enzyme is an enzyme obtainable from a microorganism belonging to Aspergillus, Candida, Fusarium, Geotrichum, Mucor, Nocardia, Penicillium, Rhizopus, Saccharomyces, Acromobacter, Acinetobacter, Alcaligenes, Chromobacterium, Escherichia, Pseudomonas, Sphingomonas, Bacillus, Burkholderia, Moraxella, Lactobacillus, Staphylococcus, Serratia, or Yarrowia. The method according to claim 1 or 5, wherein said enzyme is an enzyme obtainable from FERM-BP 5740.

Inventors: ISHII TAKESHI, MITSUDA SATOSHI, OHTA HIROMICHI, SUGAI TAKESHI, ISHII, TAKESHI, MITSUDA, SATOSHI, OHTA, HIROMICHI, SUGAI, TAKESHI
Applicants: SUMITOMO CHEMICAL CO, SUMITOMO CHEMICAL COMPANY, LIMITED
Application year: 1998
Main classification: C12P41
IPC codes: C07C233, C12N9, C12P41, C12P13